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(SOCS3) gene and suppress IL-6-activated signal transducer and activator
of transcription 3 (STAT3) activation in vascular endothelial cells
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The atherogenic cytokine IL-6 (interleukin-6) induces pro-
inflammatory gene expression in VECs (vascular endothelial
cells) by activating the JAK (Janus kinase)/STAT3 (signal
transducer and activator of transcription 3) signalling pathway,
which is normally down-regulated by the STAT3-dependent
induction of the E3 ubiquitin ligase component SOCS3
(suppressor of cytokine signalling 3). Novel treatments based on
the regulation of SOCS3 protein levels could therefore have value
in the treatment of diseases with an inflammatory component,
such as atherosclerosis. To this end we carried out a screen of 1031
existing medicinal compounds to identify inducers of SOCS3 gene
expression and identified the flavanoids naringenin and flavone
as effective inducers of SOCS3 protein, mRNA and promoter
activity. This was in contrast with the action of traditional
JAK/STAT3 inhibitors and the polyphenol resveratrol, which
effectively suppress SOCS3 gene expression. Both naringenin
and flavone also effectively suppressed IL-6-stimulated
phosphorylation of STAT3 (Tyr705) which led to suppression
of IL-6-induction of the atherogenic STAT3 target gene MCP1
(monocyte chemotactic protein-1), suggesting that their ability
to induce SOCS3 gene expression is STAT3-independent.
Supporting this idea was the observation that the general kinase
inhibitor compound C inhibits flavone- and cAMP-dependent,
but not JAK-dependent, SOCS3 induction in VECs. Indeed,
the ability of flavanoids to induce SOCS3 expression requires
activation of the ERK (extracellular-signal-regulated kinase)-
dependent transcription factor SP3, and not STAT3. In the present
paper we therefore describe novel molecular actions of flavanoids,
which control SOCS3 gene induction and suppression of STAT3
signalling in VECs. These mechanisms could potentially be
exploited to develop novel anti-atherogenic therapies.
Key words: flavanoid, gene expression, interleukin-6 (IL-6),
Janus kinase/signal transducer and activator of transcription
(JAK/STAT), suppressor of cytokine signalling 3 (SOCS3).
INTRODUCTION
Unchecked chronic inflammation is now thought to be
responsible for many cancers and deadly cardiovascular diseases,
including atherosclerosis. Chronic inflammation is associated
with increased inflammatory activity associated with increased
levels of pro-inflammatory cytokines in the circulation, including
IL-1 (IL is interleukin), IL-6 and TNFα (tumour necrosis factor
α) [1,2]. IL-6, along with TNFα and IL-1, is known to play a
key role in B-cell maturation and T-cell differentiation, as well
as driving acute inflammatory responses. However, sustained
IL-6 production is involved in chronic low-level inflammation
associated with many diseases, including obesity and insulin
resistance, inflammatory bowel diseases, rheumatoid arthritis,
sepsis, several forms of cancer and atherosclerosis [3,4]. Indeed,
IL-6 has been detected in atherosclerotic plaques [1], and
prolonged elevation of IL-6 is strongly associated with increased
levels of cholesterol and hypertension [5,6]. Moreover, high IL-
6 levels in elderly patients are associated with a 2-fold increase
in both cardiovascular and other causes of mortality [7]. IL-6
affects VECs (vascular endothelial cells) by triggering counter-
productive angiogenesis, through VEGF (vascular endothelial
growth factor) production, and increasing the secretion of
chemokines, such as MCP-1 (monocyte chemotactic protein-
1), which recruit monocytes to the inflamed endothelium [1].
Signalling by IL-6 in VECs occurs through the IL-6R (IL-6
receptor) complex, composed of an IL-6-binding α chain (IL-
6Rα) and gp130, which interacts with IL-6Rα [8]. It is IL-6R
‘trans-signalling’ [9], where IL-6 binds to soluble forms of IL6-
Rα (sIL6-Rα) and triggering hyperactivation of gp130, that is
thought to underlie the pro-inflammatory actions of IL-6 in a
variety of diseases, including atherosclerosis [3]. Binding of the
IL-6/sIL-6R complex to gp130 leads to receptor clustering and
activation of the JAK (Janus kinase)/STAT3 (signal transducer
and activator of transcription 3) signalling pathway and induction
of pro-inflammatory IL-6-responsive genes, including MCP-1 and
ICAM1 (intercellular adhesion molecule 1) [10].
Clearly, regulation of pro-inflammatory signalling is vital
to prevent runaway inflammation, since progression of many
diseases is associated with enhanced STAT3 activity. One
mechanism for down-regulating JAK/STAT signalling is via the
SOCS (suppressor of cytokine signalling) family of proteins
[11], which are often induced directly by the same JAK/STAT
pathway they inhibit, forming a classical negative-feedback
loop [12]. For example, SOCS3 binds to JAK-phosphorylated
receptors, via the SOCS3 SH (Src homology) domain (SH2),
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thereby inhibiting JAK/STAT3 signalling, and targeting SH2-
bound proteins for proteasomal degradation [13]. Consistent with
its role as a negative regulator of inflammatory signalling, SOCS3
expression is increased at sites of acute and chronic inflammation
[14], and IL-6 has been reported to promote acute and chronic
inflammatory disease in the absence of SOCS3 [15]. Moreover,
conditional deletion of the Socs3 gene in haemopoietic and
endothelial cells of transgenic mice results in death caused by
severe inflammatory lesions in the peritoneal and pleural cavities
[16], illustrating its important protective role. Cell-permeable
forms of recombinant SOCS3 have also been used to effectively
suppress pathogen-induced acute inflammation by reducing the
production of inflammatory cytokines, attenuating liver apoptosis
and limiting haemorrhagic necrosis [17]. Clearly novel treatments
based on the regulation of SOCS3 levels in cells could have
value in the treatment of diseases such as atherosclerosis where
there is hyperactivation of JAK/STAT3 signalling. To this end,
we have identified the heterocyclic small molecules naringenin
and flavone as small molecules that display the novel combined
actions of IL-6-promoted STAT3 inhibitor and SOCS3-inducer in
VECs. This is in contrast with the structurally related molecule
resveratrol and other ‘traditional’ JAK inhibitors, which inhibit
both IL-6-promoted STAT3 activation and SOCS3 induction. We
suggest that by understanding the anti-inflammatory signalling
mechanisms of small molecules such as naringenin and flavone,
this may pave the way to the development of novel therapies based
on the suppression of pro-inflammatory cytokine signalling.
EXPERIMENTAL
Materials
ECL reagents and secondary antibodies (horseradish peroxidase-
conjugated anti-rabbit-IgG and horseradish peroxidase-
conjugated anti-mouse-IgG) were bought from GE Healthcare.
HUVECs (human umbilical vein endothelial cells) and
endothelial cell growth medium 2 were obtained from PromoCell.
Dulbecco’s PBS was from Sigma–Aldrich. Forskolin, rolipram,
PMA, compound C and MG132 were obtained from Merck.
5,7-dihydroxy-2-(4-hydroxyphenyl) chroman-4-one (naringenin)
and 5-[(E)-2-(4-hydroxyphenyl)-vinyl]-1,3-benzenediol (trans-
resveratrol) were from Sigma–Aldrich and Indofine Chemical
Company. All other chemicals were purchased from Sigma–
Aldrich, apart from 5-[(Z)-2-(4-hydroxyphenyl)-vinyl]-1,3-
benzenediol (cis-resveratrol; Caymen Chemical Company),
2-phenyl-1H-quinolin-4-one (Synchem) and 3-phenyl-4H-
chromen-4-one (isoflavone; Maybridge). The NINDS-II [NINDS
(National Institute for Neurological Disorders and Stroke)
Custom Collection II] was obtained from MRCT (Medical
Research Council Technology).
Plasmids
The minimal mouse Socs3 promoter construct (pGL3-SOCS3-
107Luc) was a gift from Professor J.G. Bode (Heinrich-Heine
University, Dusseldorf, Germany) with permission from Professor
Shlomo Melmed (Cedars-Sinai Medical Center, West Hollywood,
CA, U.S.A.). This plasmid contains the promoter region − 107
to + 929 of the murine Socs3 gene fused to the coding region
of firefly luciferase as described previously [18]. PGL3-SOCS3-
107Luc constructs mutated to disrupt the putative SP3, distal and
proximal STAT-binding regions (dSTAT and pSTAT respectively),
as described previously [19], were also obtained from Professor
J.G. Bode. The QuikChange® Site-Directed Mutatgenesis kit
(Agilent) was used to introduce mutations into vectors pGL3-
SOCS3-107Luc, pGL3-SOCS3-107-pSTAT, pGL3-SOCS3-107-
SP3 and pGL3-SOCS3-107-pSTAT-SP3, using primers 5′-GCC-
TTTCAGTGCAGAGTAAAGCTTAAACATTACAAGAAGAC-
CGGCCGGGC-3′ (forward) and 5′-GCCCGGCCGGTCTTCT-
TGTAATGTTTAAGCTTTACTCTGCACTGAAAGGC-3′ (re-
verse), to disrupt the putative AP1 site (G− 105TGACTAA− 98 to
A− 105AGCTTAA− 98). Mutations were also introduced into ve-
ctors pGL3-SOCS3-107Luc, pGL3-SOCS3-107-pSTAT, pGL3-
SOCS3-107-SP3 and pGL3-SOCS3-107-pSTAT-SP3, using
primers 5′-GCCTTTCAGTGCAGAGTAAAGCTTAAACATC-
CCAGGAAGACCGGCCGGGC-3′ (forward) and 5′-GCCC-
GGCCGGTCTTCCTGGGATGTTTAAGCTTTACTCTGCAC-
TGAAAGGC-3′ (reverse), to disrupt both the putative AP1-
binding site (G− 105TGACTAA− 98 to A− 105AGCTTAA− 98)
together with the putative dSTAT site (T− 95TACAAGAA− 87
to T− 95CCCAGGAA− 87). The SP3-Luc (pAldGCB4luc; [19])
reporter construct was a gift from Professor Gerald Thiel
(University of Saarland, Homberg, Germany), the STAT reporter
construct was from Dr Timothy Palmer (University of Glasgow,
Glasgow, Scotland, U.K.) and the AP1 reporter was from Pro-
fessor Walter Kolch (University College Dublin, Dublin, Ireland).
Cell culture and transfections
COS-1 and HEK (human embryonic kidney)-293 cells were
grown in 75 cm2 tissue culture flasks in DMEM (Dulbecco’s
modified Eagle’s medium; Sigma–Aldrich) supplemented with
10% (v/v) FBS (Sigma–Aldrich), 2 mM glutamine and 2% (v/v)
penicillin/streptomycin (Sigma–Aldrich) at 37 ◦C in a humidified
5% (v/v) CO2 atmosphere. HUVECs were grown in human
endothelial cell growth medium 2 (PromoCell) at 37 ◦C in a
humidified 5% (v/v) CO2 atmosphere.
Library screening
A 1.7 kbp fragment of the human SOCS3 promoter cloned
into pGL3-Basic (hSOCS3-1.7kbp) was provided by Dr Jason
Mathews (University of Toronto, Toronto, ON, Canada) [20].
A minimal promoter truncate was then generated with the
QuikChange® II Site-Directed Mutagenesis kit (Agilent) using
this promoter fragment as an initial template. The primers used
were hSOCS3-1.1kbp (forward, 5′-GCCGAGGCTGGGTAGC-
CCCTGCTCGCGGCC-3′, and reverse, 5′- GGCCGCGAGCA-
GGGGCTACCCAGCCTCGGC-3′). The resulting minimal pro-
moter fragment was then excised from pGL3-Basic and subcloned
into the multiple-cloning site of the pGL4-Basic vector (Promega)
to generate the pGL4-hSOCS3-1.1 vector. For the NINDS-II
library screen, COS-1 cells were seeded on to 96-well microtitre
plates and then grown to approximately 80–90% confluence.
Cells were then transfected with pGL4-hSOCS3-1.1 plus a Renilla
luciferase reporter construct (pGL4.74) using DOTAP transfec-
tion agent (Roche), according to the manufacturer’s instructions.
The next day the medium was replaced with 200 μl of DMEM
plus 10% (v/v) FBS containing 100 μM of individual compounds
from the NINDS-II (MicroSource Discovery Systems) library.
After overnight incubation the medium containing the compounds
was removed and the cells washed with PBS. Cells were then
lysed with passive lysis buffer (Promega) for 20 min with rocking
at room temperature (18 ◦C). Cell lysates were then collected and
20 μl samples were assayed in triplicate for luciferase activity
using the Promega Dual Luciferase Reporter Assay System
according to the manufacturer’s protocols. Luciferase activities
were measured using a BMG Labtech luminometer.
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Immunoblotting
Cell lysates were prepared in sample buffer [50 mM Tris/HCl
(pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) 2-
mercaptoethanol, 12.5 mM EDTA, 0.02% Bromophenol Blue
and 100 mM DTT]. Protein samples were then separated by
SDS/PAGE (10% gels), transferred on to nitrocellulose, blocked
for 1 h at room temperature in 5% (w/v) BSA, and then
immunoblotted with antibodies specific for SOCS3 (Santa Cruz
Biotechnology), phospho-STAT3 (Tyr705), total STAT3 protein,
phospho-ACC (acetyl-CoA carboxylase) (Ser79), total VASP
(vasodilator-stimulated phosphoprotein), phospho-VASP (Ser157)
or phospho-ERK1/2 (extracellular-signal-regulated kinase 1/2)
(Thr202/Tyr204) and total ERK1/2 (New England Biolabs).
Immunoblots were developed using ECL chemiluminescence (GE
Healthcare).
RT (reverse transcription)–PCR
Total RNA was isolated from HUVECs using an RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions.
RT–PCRs were carried out in a 25 μl reaction mixture
containing 5–10 ng of RNA, 0.4 mM dNTPs and 0.6 μM of each
primer using the OneStep RT-PCR Kit (Qiagen). The primer
sequences used were: hSOCS3 (human SOCS3; forward, 5′-
CACATGGCACAAGCACAAGA-3′, and reverse, 5′-AAGTGT-
CCCCTGTTTGGAGG-3′), hActin (human actin; forward, 5′-C-
TGGCACCCAGCACAATG-3′, and reverse, 5′-GCCGATCC-
ACACGGAGTACT-3′) and hMCP-1 (human MCP-1; for-
ward, 5′-GCTCAGCCAGATGCAATCAA-3′, and reverse, 5′-
GGAGTTTGGGTTTGCTTGTC-3′). Reactions were carried out
in a thermocycler with the following settings: 30 min at 50 ◦C,
15 min at 95 ◦C, 30 cycles of 30 s at 94 ◦C, 30 s at 50 ◦C and
1 min at 72 ◦C, followed by 10 min at 72 ◦C. PCR products were
visualised on 2% (w/v) agarose gels following ethidium bromide
staining.
cAMP assay
HUVECs were incubated with pharmacological stimuli in 30 mm
dishes for 5 h [37 ◦C, 5% (v/v) CO2], washed with PBS (1×1 ml)
and then incubated with 300 μl/dish of sample diluent from the
DetectX High Sensitivity Direct Cyclic AMP Chemiluminescent
Immunoassay kit from Arbor Assays. Cells were incubated with
occasional mixing for a further 10 min at room temperature,
scraped into Eppendorf tubes and then centrifuged at 1000 g for
15 min at 4 ◦C. Supernatants were transferred to fresh tubes and
frozen at − 70 ◦C. Detection of cAMP levels in standards and
experimental samples was performed according to the
manufacturer’s protocols and chemiluminescent signals were
captured using a BMG Labtech luminometer set to a 0.1 s read
time per well of a 96-well plate.
Statistics
Data were analysed using one-way ANOVA with a Tukey–Kramer
post-test.
RESULTS AND DISCUSSION
Flavanoids induce SOCS3 gene expression independently of JAK
and STAT3 activation
In order to understand the molecular control of SOCS3 gene
expression we carried out a high-throughput screen of small
molecules capable of inducing the expression of the minimal
Figure 1 A high-throughput screen of medicinal compounds identifies
naringenin as a potent inducer of SOCS3 gene expression
Luciferase activity data [RLU (relative light units)] derived from a screen of a human SOCS3
minimal promoter/luciferase reporter construct transfected into COS-1 cells and screened with
1031 compounds from the 1040 compound NINDS-II compound collection as described in the
Materials and methods section. The level of induction of SOCS3 transcriptional activity induced
by narigenin and apigenin treatment is shown with arrows, together with their relative structures.
human SOCS3 gene promoter [21] in a COS-1 cell-based dual-
luciferase reporter assay. For the screen we used the NINDS-
II medicinal compound library that was originally compiled
by MicroSource Discovery Systems which we obtained from
MRCT. The library consists of 1040 U.S.A. FDA (Food and
Drug Administration)-approved compounds of known medicinal
benefit, all at 100 μM. SOCS3 promoter-expressing COS-1 cells
were stimulated for 16 h with each compound and then luciferase
activities were determined using a luminometer. The details of
individual compounds and their respective abilities to regulate
SOCS3 promoter activity are detailed in the Supplementary Data
File (at http://www.biochemj.org/bj/454/bj4540283add.htm). Of
particular note from the screen was the observation that
two structurally related flavanoid compounds, 5,7-dihydroxy-
2-(4-hydroxyphenyl) chroman-4-one (naringenin) and 5,7-
dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one (apigenin),
both produced a robust (approximately 4-fold) induction of
SOCS3 promoter activity (Figure 1). Intriguingly, dietary
naringenin is normally considered to have a positive bioactive
effect on human health as a free radical scavenging antioxidant,
an anti-inflammatory agent, an inducer of carbohydrate
metabolism and immune system modulator [22]. Moreover,
naringenin treatment has been shown to correct dyslipidaemia,
hyperinsulinaemia and obesity, and attenuate atherosclerosis in
mouse models of cardiovascular disease [23]. With this in mind,
and as a first step to identifying potential sites for future
pharmaceutical intervention to treat cardiovascular disease, we
sought to investigate the molecular basis underlying the ability
of naringenin to induce SOCS3 gene activity in HUVECs, a cell
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Figure 2 Naringenin inhibits cytokine-induced phosphorylation of STAT3 on Tyr705
(a) HUVECs were stimulated for 5 h with IL-6Rα (25 ng/ml) plus the indicated concentrations of IL-6, in the presence or absence of 100 μM naringenin. Cell extracts were then prepared and
immunoblotted with anti-STAT3 and anti-phospho-STAT3 (Tyr705) antibodies as indicated. Densitometric values from three independent experiments are expressed as a graph in the right-hand
panel (means +− S.E.M.; n = 3). Significant increases in STAT3 tyrosine phosphorylation, relative to cells stimulated with diluent alone are indicated (**P < 0.01 and ***P < 0.001 respectively),
as are significant decreases in STAT3 tyrosine phosphorylation in IL-6 plus naringenin-treated cells relative to cells treated with naringenin alone (#P < 0.05 and ###P < 0.001 respectively). (b)
HUVECs were stimulated for the indicated times with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the presence or absence of 100 μM naringenin. Tyrosine phosphorylation of STAT3 was determined
by immunoblotting cell extracts with anti-STAT3 and anti-phospho-STAT3 (Tyr705) antibodies. Densitometric values from three independent experiments are expressed as a graph in the right-hand
panel (means +− S.E.M.; n = 3). Significant increases in STAT3 tyrosine phosphorylation relative to cells stimulated with diluent alone are indicated (**P < 0.01 and ***P < 0.001 respectively), as
are significant decreases in STAT3 tyrosine phosphorylation in IL-6 plus naringenin-treated cells relative to cells treated with naringenin alone (##P < 0.01 and ###P < 0.001 respectively).
model that is used routinely to study vascular endothelial cell
function and pathology.
We first examined the effects of naringenin on IL-6-regulated
STAT3 activation, since STAT3 is a principle regulator of SOCS3
expression in HUVECs [24]. We found that a 5 h treatment with
100 μM naringenin was able to significantly suppress the ability
of IL-6 (5 ng/ml) to promote the activation-dependent Tyr705
phosphorylation of STAT3 in HUVECs [28.6 +− 3.1% reduction(n = 3, P < 0.001); Figure 2a]. A time-course of IL-6-promoted
STAT3 Tyr705 phosphorylation demonstrated that naringenin
began to exert a significant inhibitory effect after approximately
3 h stimulation (Figure 2b). Another potential mechanism for
inhibition of STAT3 activation is through inhibition of ERK-
dependent STAT3 phosphorylation on Ser727, which is required
for full STAT3 transcriptional activity [25]. However, Western
blotting with phospho-specific antibodies revealed that incubation
with naringenin did not affect the ability of IL-6 to activate ERK or
promote STAT3 phosphorylation on Ser727 (Supplementary Fig-
ure S1 at http://www.biochemj.org/bj/454/bj4540283add.htm).
From these results it is clear that 100 μM naringenin effectively
inhibits tyrosine phosphorylation of STAT3 and it is therefore
unlikely that the effects of naringenin on SOCS3 induction are
related to activation of STAT3 signalling. Indeed, results suggest
that the ability of naringenin to inhibit tyrosine phosphorylation
of STAT3, and yet induce SOCS3 expression, may occur through
distinct signalling mechanisms.
To test this idea further, we examined the abilities of a range
of structurally related flavanoids to both induce SOCS3 promoter
activity and inhibit STAT3 Tyr705 phosphorylation (Table 1). These
results clearly demonstrated a lack of correlation between the
ability of flavanoids to induce SOCS3 promoter activity and inhibit
STAT3 tyrosine phosphorylation (Table 1). For example, the level
of suppression of IL-6-promoted STAT3 activation exhibited by
100 μM naringenin was comparable with that exerted by the
naturally occurring STAT3 inhibitor 100 μM trans-resveratrol
[26]; however, of the two, naringenin was the most effective
at inducing SOCS3 promoter activity (Table 1). Moreover,
flavone, which represents the de-hydroxylated core-structure of
naringenin, was found to be a much more effective inhibitor
of STAT3 Tyr705 phosphorylation than naringenin, yet induced
SOCS3 promoter activity to similar level as naringenin (Table 1).
To examine these effects further we investigated the ability of
100 μM flavone and 100 μM resveratrol to induce the expression
of SOCS3 protein in HUVECs (Figure 3a). In this case cells
were also incubated in the presence or absence of the proteasome
inhibitor MG132 (Figure 3a), which prevents the proteolytic
degradation of newly synthesized SOCS3 by the ubiquitin–
proteasome system [10]. We also examined the effects of 100 μM
flavone and 100 μM resveratrol treatment on the levels of SOCS3
mRNA and mRNA levels of a STAT3-target gene, the atherogenic
chemokine MCP1, in HUVECs (Figure 3b). Trans-resveratrol
proved to be an effective inhibitor of IL-6-promoted SOCS3
protein and mRNA expression in HUVECs (Figures 3a and 3b),
exerting similar inhibitory effects to two commercially available
JAK inhibitors, INCB018429 and TG101348, which strongly
suppress SOCS3 induction by IL-6 (Figure 3c). In contrast,
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Table 1 Naringenin and its heterocyclic core, flavone, display the combined actions of STAT3 inhibitor and inducer of SOCS3 promoter activity
HUVECs were stimulated for 5 h with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the presence or absence of 100 μM of the compounds indicated. Cell lysates were then prepared and immunoblotted
with anti-STAT3 and anti-phospho-STAT3 (Tyr705) antibodies. Immunoblots from three separate experiments were quantified and densitometric values (means +− S.E.M.) are shown in the third
column. Representative blots from immunoblot experiments are given in Supplementary Figure S2 (at http://www.biochemj.org/bj/454/bj4540283add.htm). Significant differences in the ability of
chemical probes to inhibit IL-6-promoted STAT3 phosphorylation are indicated [*P < 0.05 and ***P < 0.001 (n = 3)]. Alternatively, COS-1 cells were transfected with a SOCS3 minimal promoter
luciferase reporter construct, as described in the Materials and methods section, and the ability of chemical probes to induce promoter activity is indicated in the fourth column as the mean percentage
change in relative light units +− S.E.M., relative to basal promoter activity. Significant increases in promoter activity are indicated [**P < 0.01 and ***P < 0.001 (n = 3)]. n.s., not significant.
Structure Name
Percentage of IL-6-stimulated STAT3 Tyr705
phosphorylation (densitometric units)
Percentage induction of SOCS3
promoter activity (relative light units)
2-Phenyl-4H-chromen-4-one (flavone) 4.2 +− 3.6*** 216.0 +− 8.8***
5,7-Dihydroxy-2-(4-hydroxyphenyl)-chroman-4-one (naringenin) 61.8 +− 5.1*** 199.6 +− 8.6***
5-[(Z)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol (cis-resveratrol) 108.4 +− 6.2 (n.s.) 164.1 +− 2.7**
3-Phenyl-4H-chromen-4-one (isoflavone) 89.3 +− 3.2 (n.s.) 162.4 +− 6.9**
1,1′-[(Z)-1,2-Ethenediyl]dibenzene (cis-stilbene) 103.6 +− 1.8 (n.s.) 127.2 +− 6.5 (n.s.)
5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol (trans-resveratrol) 65.3 +− 2.4* 110.7 +− 5.5 (n.s.)
1,1′-[(E)-1,2-Ethenediyl]dibenzene (trans-stilbene) 102.1 +− 2.3 (n.s.) 106.9 +− 2.7 (n.s.)
4H-Chromen-4-one (chromone) 99.8 +− 3.4 (n.s.) 96.6 +− 3.8 (n.s.)
flavone was found to be an effective inducer of SOCS3 protein
and mRNA levels in HUVECs, inducing levels comparable with
stimulation with a combination of the adenylate cyclase activator
forskolin and the cAMP-specific PDE (phosphodiesterase) 4
inhibitor rolipram (F/R; Figure 4), and yet suppressed mRNA
levels of MCP1 to levels comparable with those achieved
following trans-resveratrol treatment (Figure 3b). This suggests
that flavone inhibits STAT3 activation independently of SOCS3
induction. Indeed, this idea is supported by the observation
that flavone can inhibit STAT3 Tyr705 phosphorylation in HEK-
293 cells, which lack an inducible SOCS3 gene (Figure 3d).
In these cells IL-6 was found to induce phosphorylation of
STAT3 on Tyr705 and this was effectively inhibited by both trans-
resveratrol and flavone, despite the lack of SOCS3 expression
(Figure 3d). Indeed, flavone was effective at inhibiting STAT3
tyrosine phosphorylation over the same range of concentrations
in both SOCS3-negative HEK-293 cells and SOCS3-positive
HUVECs (Figure 3e). Together these results demonstrate that
the flavanoids naringenin and flavone suppress cytokine-induced
STAT3 activation through SOCS3-independent mechanisms and,
conversely, induce SOCS3 gene activity through JAK/STAT3-
independent mechanisms.
Compound C antagonizes flavone-induced SOCS3 expression
We next sought to determine the molecular mechanisms by which
flavone induces SOCS3 gene expression in HUVECs and first
investigated the role of AMPK (AMP-activated protein kinase),
since previous work implicates a role for flavanoids in modulating
AMPK activity [27]. To this end we used compound C, which
is generally marketed as an inhibitor of AMPK; however, a
number of off-target effects have been reported in the literature
[28]. Intriguingly we found that 10 μM compound C effectively
inhibited flavone-induced SOCS3 expression, but not inhibition
of IL-6-promoted STAT3 activation in HUVECs (Figure 4a).
This suggests that compound C inhibits downstream signalling
from flavone to SOCS3 gene induction. Stimulation of HUVECs
with flavone was found to elicit a degree of AMPK activation,
as determined by immunoblotting cell extracts with phospho-
specific antibodies that detect the AMPK substrate ACC (Ser79);
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Figure 3 Naringenin and flavone, but not resveratrol, induce SOCS3 protein and mRNA expression
(a) HUVECS were pre-incubated for 30 min in the presence or absence of MG132 (10 μM), to stabilize SOCS3 protein expression, and then for a further 5 h with IL-6 (5 ng/ml)/IL-6Rα (25 ng/ml)
plus or minus the indicated chemical probes (100 μM). Cell extracts were prepared and immunoblotted with anti-SOCS3 or tubulin antibodies. (b) HUVECs were stimulated for 5 h in the presence or
absence of IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml), forskolin/rolipram (F/R), 100 μM trans-resveratrol or 100 μM flavone. Cellular mRNA was then extracted and subjected to RT–PCR with specific
primers to either human SOCS3, MCP-1 or actin, as described in the Materials and methods section. Results are representative of three separate experiments. (c) HUVECs were incubated in the
presence or absence of MG132, IL-6 (5 ng/ml)/IL-6Rα (25 ng/ml), flavone, trans-resveratrol or the JAK inhibitors (10 μM) INCB018429 or TG101348. Cell extracts were probed with anti-SOCS3,
anti-total-STAT3 or anti-phospho-STAT3 antibodies as indicated. (d) HEK-293 cells were stimulated with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the presence or absence of the indicated treatments.
Cell extracts were then immuoblotted with anti-SOCS3, anti-STAT3 and anti-phospho-STAT3 antibodies. HUVEC extracts from cells that had been stimulated with F/R for 5 h were used as a positive
control for immunoblots. (e) HEK-293 cells (top panel) and HUVECs (bottom panel) were incubated for 5 h with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the presence or absence of the indicated
concentrations of flavone. Cell extracts were then prepared and immunoblotted with anti-STAT3 and anti-phospho-STAT3 antibodies as indicated.
however, direct activation of AMPK with the specific AMPK
agonist 10 μM A769622 failed to induce SOCS3 expression
(Figure 4a). In addition, flavone-activated AMPK does not
appear to be involved in the inhibition of STAT3 activation,
since compound C treatment blocked ACC phosphorylation in
response to flavone, but had little effect on flavone-inhibited
STAT3 phosphorylation (Figure 4a). These results suggest that
although flavone can activate AMPK in HUVECs, this activity
is not linked to the induction of the SOCS3 gene or inhibition of
STAT3 activation. However, given that compound C effectively
inhibits flavone action on the SOCS3 gene, we decided to
use compound C as a chemical probe to identify signalling
pathways that may couple flavone stimulation to SOCS3
induction.
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Figure 4 Compound C inhibits flavone- and cAMP-stimulated SOCS3 induction
(a) HUVECs were pre-incubated for 30 min with either 100 μM flavone, 10 μM compound C or 10 μM of the AMPK activator A769662 and then stimulated for 5 h in the presence or absence of IL-6
(5 ng/ml)/IL-6Rα (25 ng/ml) plus MG132 (10 μM) as indicated. Cell extracts were then prepared and immunoblotted with the antibodies indicated. (b) HUVECs were incubated with the indicated
combinations of pharmacological agents in the presence of 10 μM MG132 to stabilize cellular SOCS3 levels. Cell extracts were then immunoblotted with anti-SOCS3 and anti-tubulin antibodies, as
indicated in the top panel, and densitometric values (means +− S.E.M.) from immunoblots are displayed as a histogram in the right-hand panel. Significant increases in SOCS3 induction relative to
cells stimulated with diluent alone are indicated (**P < 0.01 and ***P < 0.001 respectively), as are significant decreases in SOCS3 induction in cells treated with compound C, Go¨6983, PD184352
and INCB018429 respectively, relative to cells treated with flavone, PMA, forskolin and rolipram (F/R) and IL-6 respectively (#P < 0.05 and ###P < 0.001).
To this end we tested the ability of compound C to inhibit
SOCS3 induction promoted by activation of the PKC (protein
kinase C) pathway, the JAK/STAT3 signalling pathway and the
cAMP cascade, since all of these pathways have previously been
implicated in controlling SOCS3 gene induction in HUVECs
[10,21,24,29]. We first activated PKC signalling in HUVECs by
stimulating cells with the phorbol ester PMA (Figure 4b).
PMA (100 nM) treatment produced a robust 4-fold increase in
SOCS3 protein expression, which was significantly inhibited
by the general PKC inhibitor 10 μM Go¨6983, but not by
10 μM compound C (Figure 4b). The fact that PMA-induced
SOCS3 expression is inhibited by Go¨6983 but not compound
C suggests that PKC activation leads to SOCS3 induction
through a pathway distinct from that regulated by flavone.
Similarly, activation of JAK/STAT3 signalling following IL-6
treatment of HUVECs also led to a significant 8-fold induction in
SOCS3 protein expression (Figure 4b), which was effectively
suppressed by co-incubation with the JAK inhibitor 10 μM
INCB018429, but not 10 μM compound C (Figure 4b). Again
this suggests that IL-6-mediated induction of SOCS3 expression
is dependent on JAK activity; however, the actions of flavone
on SOCS3 expression must occur independently of JAK/STAT3
signalling since compound C treatment had little effect on IL-
6 signalling. To test the role of cAMP in mediating SOCS3
induction, HUVECs were stimulated with a combination of
10 μM forskolin and 10 μM rolipram to elevate intracellular
cAMP levels (Figure 4b). cAMP has previously been shown to be
a potent inducer of SOCS3 expression in HUVECs through the
combined action of the ERK and EPAC1 signalling pathways
[29,30]. Accordingly, elevations in intracellular cAMP levels
following forskolin/rolipram treatment provoked a significant 6-
fold increase in SOCS3 protein expression (Figure 4b), which
was significantly inhibited (by approximately 30%, P < 0.05)
by both 10 μM compound C and the inhibitor of ERK activation
1 μM PD184352 [31]. That cAMP-induced SOCS3 induction was
inhibited by both compound C and an ERK inhibitor indicates
that flavone may use similar signalling mechanisms to those
used by cAMP to induce SOCS3 gene expression. We therefore
investigated the roles of cAMP and ERK signalling in mediating
the actions of flavone on SOCS3 gene induction.
SOCS3 gene induction by flavone is dependent on ERK activity
We have previously demonstrated that induction of SOCS3 gene
expression by cAMP is dependent on the combined actions of
cAMP on EPAC1 activation and ERK signalling in HUVECs
[29,32]. We therefore investigated the involvement of these two
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Figure 5 ERK MAPK is required for flavone induced SOCS3 expression, but not for inhibition of STAT3 phosphorylation
(a) COS-1 cells were transfected with a luciferase reporter construct encoding the minimal murine Socs3 promoter [24]. In addition, cells were co-transfected with Renilla luciferase vector to
normalize luciferase activity and to correct for transfection efficiency. Cells were then stimulated overnight with either 100 μM flavone or 100 nM PMA, in the presence of 1 μM of the MEK inhibitors
PD184352 or AZD6244. Cell extracts were prepared and luciferase activities from three separate experiments were quantified. Significant increases in luciferase activity relative to diluent-treated cells
are indicated [***P < 0.001 (n = 3)]. Significant reductions in luciferase activity relative to stimulated cells are also indicated (###P < 0.001). (b) HUVECs pre-incubated with either PD184352
or AZD6244 and then stimulated with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml), flavone or trans-resveratrol. Cell extracts were then immunoblotted with antibodies against SOCS3, and total and
phosphorylated forms of ERK and STAT3 as indicated.
pathways in mediating induction of SOCS3 by flavone. Given
that flavanoids inhibit CK2 (casein kinase 2) [33], an enzyme
known to antagonize cAMP production [34], and that resveratrol
has recently been described as an inhibitor of PDE4 activity [35],
we decided to test the involvement of cAMP in flavone-induced
SOCS3 induction and inhibition of STAT3 activation. We found
that flavone, resveratrol and rolipram were all able to enhance
the ability of the cAMP-elevating agent forskolin to inhibit
IL-6-promoted STAT3 activation (Supplementary Figure S3a at
http://www.biochemj.org/bj/454/bj4540283add.htm), indicating
that both flavone and resveratrol could potentially enhance cAMP
production either through inhibition of CK2 or PDE4. However,
direct measurement of cAMP levels following treatment of
HUVECs with combinations of flavone, resveratrol, rolipram
and forksolin demonstrated that rolipram, and to a minor extent
resveratrol, but not flavone, were able to potentiate forskolin-
induced cAMP synthesis in HUVECs (Supplementary Figure
S3b), indicating that flavone induces SOCS3 gene induction
independently of cAMP. To determine whether the combined
actions of flavanoid treatment and IL-6 stimulation effected cAMP
levels, we examined whether co-stimulation of HUVECs with IL-
6 and forskolin, and either flavone, reseveratrol or rolipram, effects
phosphorylation of the PKA (protein kinase A) substrate VASP
on Ser157 (Supplementary Figure S3c). Results demonstrated
that IL-6 did not promote VASP Ser157 phosphorylation, after
either 30 min or 5 h stimulation (Supplementary Figure S3c). In
contrast, a combination of forskolin and IL-6 promoted a robust
phosphorylation of VASP after 30 min stimulation, which was
enhanced by 5 h co-treatment with rolipram and, to a lesser extent,
resveratrol, but not by flavone (Supplementary Figure S3c). Taken
together these results indicate that the ability of flavone to induce
SOCS3 expression and inhibit IL-6 promoted STAT3 activation
occurs independently of elevations in intracellular cAMP in
HUVECs.
The results shown in Figure 4(b) indicate that induction of
SOCS3 expression by flavone may share downstream signalling
with the cAMP signalling cascade. Since flavone does not
appear to elevate intracellular cAMP levels itself in HUVECs
(Supplementary Figure S3) then it could possibly be interacting
with downstream signalling elements. In this regard we have
previously shown that elevations in intracellular cAMP activates
the MAPK (mitogen-activated protein kinase) ERK in HUVECs,
and this activation appears to be required for cAMP to induce
SOCS3 gene expression [24,32]. We therefore investigated
whether ERK activation is also a prerequisite for flavone-
induced SOCS3 expression. We therefore examined whether
two inhibitors of ERK activation, the MEK (MAPK/ERK
kinase) inhibitors PD184352 and AZD6244, could antagonize the
actions of flavone on SOCS3 induction and inhibition of STAT3
activation. We found that both inhibitors effectively blocked
the ability of flavone to induce SOCS3 promoter activity in
transfected COS-1 cells and SOCS3 protein synthesis in HUVECs
(Figures 5a and 5b). We also noted that, although both ERK
inhibitors effectively blocked flavone-induced SOCS3 production
in HUVECs, flavone did not produce an appreciable activation of
ERK (Figure 5b), indicating that it is basal, rather than stimulated,
levels of ERK that are required for SOCS3 gene induction by
flavone in these cells.
We also noted that neither PD184352 nor AZD6244 affected
the ability of resveratrol and flavone to block IL-6-promoted
STAT3 activation (Figure 5b), indicating that the actions of
these compounds on STAT3 activation occur independently
of ERK and SOCS3 induction. This is borne out by the
observation that naringenin treatment of HUVECs failed to
affect IL-6-promoted phosphorylation of the STAT3 ERK-target
site, Ser727 (Supplementary Figure S1b). Indeed, IL-6-promoted
phosphorylation of STAT3 on Tyr705 appears to be enhanced,
rather than inhibited, in the presence of PD184352 and AZD6244
(Figure 5b). These results reinforce the idea that transcription
factors other than STAT3 are responsible for SOCS3 gene
induction in response to flavone treatment. Indeed, our previous
work has demonstrated that the activity of the minimal SOCS3
promoter is dependent on basal activity of ERK and the ERK-
targeted transcription factors AP1 and SP3, in addition to STAT3
[24]. We therefore examined the role of these three transcription
factors in supporting the activity of the SOCS3 promoter in
luciferase reporter assays as described previously [21,24]. We
first transfected COS-1 cells with luciferase reporter constructs
containing various lengths of the murine Socs3 promoter spanning
− 49 to − 2757 nt from the initiating ATG (Figure 6a). We
found that naringenin treatment led to a significant approximate
1.5-fold induction of the full-length − 2757 promoter and the
− 107 minimal promoter (Figure 6a). Further promoter truncation,
removing the AP1- and STAT-binding sites, was associated
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Figure 6 SOCS3 gene induction by naringenin is dependent on SP3 transcription factors
(a) COS-1 cells were transfected with firefly luciferase reporter constructs containing Renilla luciferase and truncates of the murine Socs3 promoter as indicated [24]. Cells were then stimulated
for 16 h with 100 μM naringenin, after which time cells were harvested and luciferase activities determined. The relative positions of putative transcription factor-binding sites within the minimal
promoter region are shown in the schematic diagram on the left-hand side of the histogram. Results are means +− S.E.M. of absolute relative light units (RLUs) from three separate experiments and
significant differences relative to cells stimulated with diluent alone are indicated (***P < 0.001). Significant reductions in naringenin-promoted luciferase activities relative to stimulated levels
obtained from the minimal Socs3 promoter construct are also indicated (###P < 0.0001). (b) COS-1 cells were transfected with vectors encoding Renilla luciferase, together with luciferase vectors
encoding the minmal murine Socs3 minimal promoter (mSOCS3-107) in which individual transcription factor-binding sites had been deleted. Cells were then stimulated for 16 h with 100 μM
naringenin, after which time cells were harvested and luciferase activities determined. Results are means +− S.E.M. of absolute RLUs from three separate experiments. Significant differences relative
to cells transfected with non-mutated promoter and stimulated with diluent alone are indicated (*P < 0.05, **P < 0.01 and ***P < 0.001). (c) COS-1 cells were transfected with luciferease reporter
constructs encoding multiple consensus DNA-binding sites for STAT, AP1 or SP3 transcription factors. Cells were then stimulated for 16 h with 100 μM naringenin or trans-resveratrol. Luciferase
activities were determined and significant increases or decreases in luciferase activity relative to diluent-treated cells are indicated [***P < 0.001 and ###P < 0.001 respectively (n = 3)]. (d) COS-1
cells were transfected with luciferease reporter constructs encoding multiple consensus DNA-binding sites for SP3 transcription factors. Cells were then stimulated for 16 h with 100 μM naringenin
in the presence or absence of either 10 μM compound C or the MEK inhibitor 10 μM AZD6244. Luciferase activities were determined (n = 3) and significant increases (***P < 0.001) or decreases
(#P < 0.05 and ##P < 0.01) in luciferase activity relative to diluent-treated cells are indicated. n.s., not significant.
with a reduction in basal, but not naringenin-stimulated, activity
(Figure 6a). However, further truncation, leading to the loss of
the SP3-binding site, led to a loss of both basal and naringenin-
stimulated promoter activity (Figure 6a), suggesting that SP3
transcription factors may be important for SOCS3 gene induction
by flavanoids. This idea is supported by further experiments
where we ablated individual transcription factor-binding sites
within the SOCS3 minimal promoter (Figure 6b). We found
that sequential deletion of the AP1- and STAT-binding sites had
little effect on naringenin-promoted SOCS3 promoter activity
(Figure 6b). However, ablation of the SP3-binding site, by itself
or in combination with the AP1- and STAT-binding sites, led
to a dramatic reduction in both basal and naringenin-stimulated
promoter activity (Figure 6b), indicating a potential role for
SP3 transcription factors in the control of SOCS3 gene activity.
This idea is supported by observations that treatment of COS-1
cells with naringenin led to an increase in both AP1 and SP3
transcription factor activity (Figure 6c), as determined by the use
of luciferase reporter constructs as described previously [24]. This
is in contrast with trans-resveratrol, which generally suppressed
AP1, STAT and SP3 transcription factor activity (Figure 6c). In
addition, and consistent with the idea that basal ERK activity is
required for regulation of SOCS3 gene activity, the ERK inhibitor
AZD6244 suppressed both basal and naringenin-stimulated SP3
transcription factor activity (Figure 6d). Moreover, basal and
naringenin-stimulated SP3 activity were also inhibited by co-
treatment with compound C, which supports the idea that SP3
transcription factors are involved in the regulation of SOCS3 gene
activity by flavanoids.
In summary, in the present paper we describe a new class of
chemical probes based on the flavone core structure that have
the novel combined actions of STAT3 inhibitor and inducer
of SOCS3 gene expression. The ability of these compounds
to induce SOCS3 gene expression appears to rely on ERK-
dependent SP3 transcription factor activation (Figure 6). Our
objective is to use these probes to identify their protein targets
in VECs. It is highly likely that the cellular target of flavone
will be a kinase or phosphatase, since flavanoids have been
reported to act on protein kinases, including the serine/threonine
kinases PKC, Aurora-A, -B and -C and AMPK, the tyrosine
kinases JAK3, PIM1 and PDGFRα (platelet-derived growth factor
receptor α) and PDGFRβα, and lipid kinases, including PI3K
(phosphoinositide 3-kinase) [27,36–39]. Identifying the protein
targets of flavone will serve as a starting point for the development
of novel therapeutics to combat chronic inflammatory diseases
where there is hyperactivation of JAK/STAT3 signalling. This
approach could have advantages over existing anti-IL-6 therapies;
for example, monoclonal antibodies against the IL-6R, e.g.
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tocilizumab [40], are in regular clinical use; however, humanized
antibodies are expensive to produce and store, have a limited
shelf life and require regular injections for effective treatment.
Current therapeutic small-molecule JAK/STAT3 inhibitors, such
as tasocitinib [41], are cheap, easy to produce and can be taken
orally, but effectively suppress SOCS3 activity [42] (Figure 3c).
Since we have yet to identify the full range of proteins targeted
by SOCS3 for proteosomal degradation [43], traditional drugs,
such as tasocitinib, may have limited anti-inflammatory actions
or unforeseen side effects when compared with the flavanoid-
based STAT3 inhibitors/SOCS3-elevating agents described in the
present paper [17]. In the experiments we carried out we used both
naringenin and flavone at concentrations up to 100 μM because
naringenin has been shown not to be cytotoxic to HUVECs at
this concentration, and is in fact anti-apoptotic [44]. High levels
of narignenin, between 200 and 400 μM, have been shown to
be cytotoxic to cancer cells [45]; however, in general, flavanoids
are not thought to be toxic and are readily bioavailable in foods;
for example ingestion of 8 ml/kg grapefruit juice will provide a
plasma concentration of naringenin of approximately 6 μM [46].
In the case of flavone, in vivo measurements have demonstrated
that flavone acetate exerts anti-neoplastic actions at a plasma
concentration of around 360 μM and is acutely lethal at 2.1 mM
[47]. Plasma concentrations of flavone acetate between 360 μM
and 2.1 mM induce delayed death [47]. Thus the actions of the
flavanoids tested in the present study occur within the tolerated
concentration range of these compounds and should therefore be
useful to the wider scientific community for further functional
testing.
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Figure S1 Naringenin has little effect on the phosphorylation of either ERK or STAT Ser727 in HUVECs
(a) HUVECs were pre-incubated for 5 h in the presence or absence of 100 μM naringenin. Cells were then stimulated with either diluent, IL-6 (5 ng/ml)/IL-6Rα (25 ng/ml) or the PKC activator
100 nM PMA. Cell extracts were then prepared and immunoblotted with anti-phospho-ERK or anti-total ERK antibodies as indicated. (b) HUVECs were pre-incubated for the times indicated with
100 μM naringenin and then stimulated for 30 min in the presence or absence of IL-6 (5 ng/ml)/IL-6Rα (25 ng/ml). Cell extracts were then immunoblotted with anti-phospho-STAT3 (Ser727) or
anti-total STAT3 antibodies as indicated.
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Figure S2 Effects of variations in flavanoid structure on the inhibition of IL-6-promoted STAT3 activation in HUVECs
(a) HUVECs were stimulated for 5 h with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the presence or absence of either 100 μM naringenin, 2-(5,7-dihydroxyphenyl) chromen-4-one, 2-(7-hydroxyphenyl)
chromen-4-one or 2-(4-hydroxyphenyl) chromen-4-one (structures are shown in the top panel). Cell lysates were then prepared and immunoblotted with anti-STAT3 and anti-phospho-STAT3
(Tyr705) antibodies as shown in the bottom panel. Results indicate that 2-(7-hydroxyphenyl) chromen-4-one and 2-(4-hydroxyphenyl) chromen-4-one are the most effective inhibitors of
IL-6-stimulated STAT3 phosphorylation in HUVECs. (b) HUVECs were stimulated for 5 h with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the presence or absence of either 100 μM 4H-chromen-4-one,
2-phenyl-4H-chromen-4-one, 2-phenyl-4H-chromen-4-one, 2-phenyl-1H-quinolin-4-one or 2-(4-hydroxyphenyl) chromen-4-one (structures are shown in the top panel). Cell lysates were then
prepared and immunoblotted with anti-STAT3 and anti-phospho-STAT3 (Tyr705) antibodies as shown in the bottom panel. Results indicate that 2-phenyl-1H-quinolin-4-one and 2-(4-hydroxyphenyl)
chromen-4-one are the most effective inhibitors of IL-6-stimulated STAT3 phosphorylation in HUVECs. (c) HUVECs were stimulated for 5 h with IL-6 (5 ng/ml) plus IL-6Rα (25 ng/ml) in the
presence or absence of either 100 μM trans-stilbene, cis-stilbene, trans-resveratrol or cis-resveratrol (structures are shown in the top panel). Cell lysates were then prepared and immunoblotted with
anti-STAT3 and anti-phospho-STAT3 (Tyr705) antibodies as shown in the bottom panel. Results indicate that trans-resveratrol is the most effective inhibitor of IL-6-stimulated STAT3 phosphorylation
in HUVECs.
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Figure S3 Flavone-induced SOCS3 expression and inhibition of STAT3 is independent of increases in intracellular cAMP levels
(a) HUVECs were stimulated for 5 h with the indicated combinations of IL-6 (5 ng/ml)/IL-6Rα (25 ng/ml), forskolin (10 μM), flavone (100 μM), trans-resveratrol (100 μM) and rolipram (10 μM).
Cell extracts were then immunoblotted with anti-SOCS3, anti-STAT3 and anti-phospho-STAT3 antibodies as indicated. (b) HUVECs were stimulated for 5 h with forskolin (10 μM) in the presence or
absence of flavone (100 μM), trans-resveratrol (100 μM) or rolipram (10 μM) as indicated. cAMP levels in cell extracts were then quantified using a luminescent ELISA-based assay, as described in
the Materials and methods of the main paper. Results are the average of an experiment carried out on three separate occasions and significant increases in cAMP levels with respect to diluent-treated
cells are indicated (*P < 0.05 and ***P < 0.001). (c) HUVECs were stimulated for either 30 min or 5 h in the presence or absence of IL-6 (5 ng/ml)/IL-6Rα (25 ng/ml) together with the indicated
combinations of forskolin, flavone, reseveratrol and rolipram. Cell extracts were then prepared and immunoblotted with anti-phospho-VASP (Ser157) and anti-tubulin antibodies.
Received 4 April 2013/12 June 2013; accepted 19 June 2013
Published as BJ Immediate Publication 19 June 2013, doi:10.1042/BJ20130481
c© The Authors Journal compilation c© 2013 Biochemical Society© 2013 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
